Ping D Liu from Newburyport, MA, age 68

Medicine Doctors

Ping Liu

view source

Specialties:

Internal Medicine

Work:

Newton Memorial Medical Center Hospitalist
175 High St FL 3, Newton, NJ 07860
9733832121 (phone), 9735798807 (fax)

Education:

Medical School
Tongji Med Univ, Wuhan City, Hubei, China
Graduated: 1992

Conditions:

Acute Pancreatitis
Bacterial Pneumonia
Cardiac Arrhythmia
Cholelethiasis or Cholecystitis
Chronic Bronchitis

Languages:

English

Description:

Dr. Liu graduated from the Tongji Med Univ, Wuhan City, Hubei, China in 1992. She works in Newton, NJ and specializes in Internal Medicine. Dr. Liu is affiliated with Overlook Medical Center.

Ping Liu

view source

Specialties:

Internal Medicine

Us Patents

Substituted Amides
view source
US Patent:

6972295, Dec 6, 2005
Filed:

Mar 12, 2003
Appl. No.:

10/387265
Inventors:

William K. Hagmann - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Shrenik K. Shah - Metuchen NJ, US
Ravindra N. Guthikonda - Edison NJ, US
Hongbo Qi - Edison NJ, US
Linda L. Chang - Wayne NJ, US
Ping Liu - Edison NJ, US
Helen M. Armstrong - Westfield NJ, US
James P. Jewell - Jersey City NJ, US
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

A61K031/4412
C07D213/70
US Classification:

514345, 546290
Abstract:

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Vla-4 Antagonists
view source
US Patent:

7514409, Apr 7, 2009
Filed:

Mar 7, 2005
Appl. No.:

10/591820
Inventors:

William K. Hagmann - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Ping Liu - Westfield NJ, US
Richard A. Mumford - Red Bank NJ, US
Thomas S. Reger - San Diego CA, US
Nicholas D. Smith - San Diego CA, US
Nicholas S. Stock - San Diego CA, US
Jasmine Zunic - San Diego CA, US
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

A61K 38/05
US Classification:

514 19
Abstract:

Compounds of Formula I are antagonists of VLA-4, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of inflammatory bowel disease including ulcerative colitis and Crohn's disease, multiple sclerosis, asthma, and rheumatoid arthritis.

Substituted Pyridyoxy Amides
view source
US Patent:

7550489, Jun 23, 2009
Filed:

Feb 1, 2008
Appl. No.:

12/012463
Inventors:

William K. Hagmann - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Shrenik K. Shah - Metuchen NJ, US
Ravindra N. Guthikonda - Edison NJ, US
Hongbo Qi - Edison NJ, US
Linda L. Chang - Wayne NJ, US
Ping Liu - Edison NJ, US
Helen M. Armstrong - Westfield NJ, US
James P. Jewell - Jersey City NJ, US
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

A61K 31/435
US Classification:

514354, 514355
Abstract:

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Substituted Amides
view source
US Patent:

7816534, Oct 19, 2010
Filed:

Apr 16, 2009
Appl. No.:

12/386336
Inventors:

William K. Hagmann - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Shrenik K. Shah - Metuchen NJ, US
Ravindra N. Guthikonda - Edison NJ, US
Hongbo Qi - Edison NJ, US
Linda L. Chang - Wayne NJ, US
Ping Liu - Edison NJ, US
Helen M. Armstrong - Westfield NJ, US
James P. Jewell - Jersey City NJ, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 31/44
C07D 213/04
C07D 401/02
C07D 403/02
C07D 239/02
US Classification:

546255, 546266, 5462681, 544238, 514256, 514336, 514340
Abstract:

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Substituted Diazepine Sulfonamides As Bombesin Receptor Subtype-3 Modulators
view source
US Patent:

8153626, Apr 10, 2012
Filed:

Dec 7, 2007
Appl. No.:

12/517836
Inventors:

Robert K. Baker - Cranford NJ, US
Linda L. Chang - Wayne NJ, US
Marc Chioda - Metuchen NJ, US
Harry R. Chobanian - Aberdeen NJ, US
Yan Guo - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Ping Liu - Westfield NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Kathleen M. Rupprecht - Cranford NJ, US
Shouwu Miao - Edison NJ, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A01N 43/62
A61K 31/55
C07D 491/00
C07D 513/00
C07D 515/00
C07D 243/10
C07D 487/12
US Classification:

514220, 540557
Abstract:

Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

Imidazole Derivatives Useful As Inhibitors Of Faah
view source
US Patent:

8455528, Jun 4, 2013
Filed:

Jun 4, 2009
Appl. No.:

12/996429
Inventors:

Linus S. Lin - Westfield NJ, US
Marc D. Chioda - Metuchen NJ, US
Ping Liu - Westfield NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 31/4174
A61K 31/4178
C07D 233/84
US Classification:

514397, 5483111
Abstract:

The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

Substituted Amides
view source
US Patent:

20050234061, Oct 20, 2005
Filed:

Apr 19, 2005
Appl. No.:

11/109076
Inventors:

William Hagmann - Westfield NJ, US
Linus Lin - Westfield NJ, US
Shrenik Shah - Metuchen NJ, US
Ravindra Guthikonda - Edison NJ, US
Hongbo Qi - Edison NJ, US
Linda Chang - Wayne NJ, US
Ping Liu - Edison NJ, US
Helen Armstrong - Westfield NJ, US
James Jewell - Jersey City NJ, US
Thomas Lanza - Edison NJ, US
International Classification:

A61K031/502
A61K031/428
A61K031/423
A61K031/4196
A61K031/405
A61K031/401
A61K031/165
US Classification:

514248000, 514367000, 514375000, 514423000, 514419000, 514617000, 514383000, 544237000, 548152000, 548217000, 548495000, 548537000
Abstract:

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Acyclic Hydrazides As Cannabinoid Receptor Modulators
view source
US Patent:

20080076805, Mar 27, 2008
Filed:

Oct 3, 2005
Appl. No.:

11/661834
Inventors:

Linus Lin - Westfield NJ, US
Ping Liu - Westfield NJ, US
International Classification:

A61K 31/4412
A61K 31/165
A61P 25/00
C07C 243/12
C07D 213/63
US Classification:

514351000, 514615000, 546300000, 564149000, 564151000
Abstract:

The acyclic hydrazides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders (including smoking cessation), the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Vehicle Records

Ping Liu
view source
Address:

20 Ballou St, Quincy, MA 02169
Phone:

6174815826
VIN:

JN8AZ1MW4BW186340
Make:

NISSAN
Model:

MURANO
Year:

2011

Resumes

Ping Liu

view source

Work:

Ping Liu

2014 to 2000
Principal Statistician 3M Pharmaceuticals, Inc

May 2005 to Feb 2012
Statistician/lead statistician on several US and Europe

Aug 2000 to Apr 2005
Lead statistician in Actinic Keratosis project University of Minnesota

Sep 1998 to Jun 2000
Consultant

Education:

The University of Texas
2007 to 2012
Ph.D in Biostatistics University of Minnesota
1998 to 2000
M.S in Biostatistics Fudan University
1992 to 1997
B.S in Genetics & Genetic Engineering Fudan University